Full metadata record

DC Field Value Language
dc.contributor.authorKim, Jong-Ho-
dc.contributor.authorBae, Sang Mun-
dc.contributor.authorNa, Moon-Hee-
dc.contributor.authorShin, Hyeri-
dc.contributor.authorYang, Yu Jin-
dc.contributor.authorMin, Kyung Hyun-
dc.contributor.authorChoi, Ki Young-
dc.contributor.authorKim, Kwangmeyung-
dc.contributor.authorPark, Rang-Woon-
dc.contributor.authorKwon, Ick Chan-
dc.contributor.authorLee, Byung-Heon-
dc.contributor.authorHoffman, Allan S.-
dc.contributor.authorKim, In-San-
dc.date.accessioned2024-01-20T15:31:21Z-
dc.date.available2024-01-20T15:31:21Z-
dc.date.created2021-09-05-
dc.date.issued2012-02-10-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/129544-
dc.description.abstractMacromolecular nanoparticles can extravasate and accumulate within tumor tissues via the passive targeting system, reflecting enhanced permeability and the retention effect. However, the unsatisfactory tumor therapeutic efficacy of the passive-targeting system, attributable to the retention of extravasated nanoparticles in the vicinity of tumor vessels, argues that a new system that facilitates intracellular delivery of nanoparticles within tumors is needed. Here, we developed hydrophobically modified glycol chitosan (HGC) nanoparticles conjugated with interleukin-4 receptor (IL-4R) binding peptides, termed I4R, and tested them in mice bearing IL-4R-positive tumors. These HGC-I4R nanoparticles exhibited enhanced IL-4R-dependent cellular uptake in tumors compared to nonconjugated nanoparticles, leading to better therapeutic and imaging efficacy. We conclude that I4R facilitates and enhances cellular uptake of nanoparticles in tumor tissues. This study suggests that the intracelluar uptake of nanoparticles in tumors is an essential factor to consider in designing nanoparticles for tumor-targeted drug delivery and imaging. (C) 2011 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER-
dc.subjectGLYCOL CHITOSAN NANOPARTICLES-
dc.subjectINTERLEUKIN-4 RECEPTOR-
dc.subjectCANCER-THERAPY-
dc.subjectAFFINITY-
dc.subjectINTERNALIZATION-
dc.subjectLOCALIZATION-
dc.subjectCHEMOTHERAPY-
dc.subjectVASCULATURE-
dc.subjectDOXORUBICIN-
dc.subjectEXPRESSION-
dc.titleFacilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2011.09.070-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, v.157, no.3, pp.493 - 499-
dc.citation.titleJOURNAL OF CONTROLLED RELEASE-
dc.citation.volume157-
dc.citation.number3-
dc.citation.startPage493-
dc.citation.endPage499-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000301980900021-
dc.identifier.scopusid2-s2.0-84857374141-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusGLYCOL CHITOSAN NANOPARTICLES-
dc.subject.keywordPlusINTERLEUKIN-4 RECEPTOR-
dc.subject.keywordPlusCANCER-THERAPY-
dc.subject.keywordPlusAFFINITY-
dc.subject.keywordPlusINTERNALIZATION-
dc.subject.keywordPlusLOCALIZATION-
dc.subject.keywordPlusCHEMOTHERAPY-
dc.subject.keywordPlusVASCULATURE-
dc.subject.keywordPlusDOXORUBICIN-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordAuthorTumor targeting-
dc.subject.keywordAuthorNanoparticles-
dc.subject.keywordAuthorHoming peptide-
dc.subject.keywordAuthorCancer therapy-
dc.subject.keywordAuthorCancer imaging-
Appears in Collections:
KIST Article > 2012
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE